REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

Yesterday 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251219:nRSS2061Ma&default-theme=true

RNS Number : 2061M  AstraZeneca PLC  19 December 2025

19 December 2025

 

 

Transaction by Person Discharging Managerial Responsibilities and Person
Closely Associated

 

 

AstraZeneca PLC (the Company) announces that, on 17 December 2025, it was
notified by Philip Broadley, Non-Executive Director, that on 17 December 2025,
Mr Broadley gifted 5,735 ordinary shares of $0.25 each in the Company, for nil
consideration, to his spouse, who is a person closely associated (PCA) to Mr
Broadley.

 

Further details are set out in the attached notifications, made in accordance
with the requirements of the EU Market Abuse Regulation (as it forms part of
UK law pursuant to the European Union (Withdrawal) Act 2018.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Philip Broadley

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director and PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code

                                                                   GB0009895292

 b)   Nature of the transaction                                    Gift of shares for nil consideration

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   0    5,735
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price
 e)   Date of the transaction                                      17 December 2025

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

e)

 

Date of the transaction

 

17 December 2025

f)

 

Place of the transaction

 

Outside a trading venue

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Gillian Broadley

 2    Reason for the notification

 a)   Position/status                                              Person Closely Associated (PCA) to Philip Broadley (PDMR)

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code

                                                                   GB0009895292

 b)   Nature of the transaction                                    Receipt of gift of shares for nil consideration

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   0    5,735
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price
 e)   Date of the transaction                                      17 December 2025

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

e)

 

Date of the transaction

 

17 December 2025

f)

 

Place of the transaction

 

Outside a trading venue

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit www.astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) .

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUWOURVSUUAUA



            Copyright 2019 Regulatory News Service, all rights reserved